112 related articles for article (PubMed ID: 24262315)
1. A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use.
Abhinay G; Dessain S; Srikanth A; Senthilkumar RL; Vidyasagar P; Praveen A; Chandrasekhar Reddy RV; Swapna Reddy E; Rajendra L
Vaccine; 2014 Jan; 32(2):209-13. PubMed ID: 24262315
[TBL] [Abstract][Full Text] [Related]
2. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture.
Nagarajan T; Reddy GS; Mohana Subramanian B; Rajalakshmi S; Thiagarajan D; Tordo N; Jallet C; Srinivasan VA
Biologicals; 2006 Mar; 34(1):21-7. PubMed ID: 16188454
[TBL] [Abstract][Full Text] [Related]
3. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody.
Perrin P; Morgeaux S; Sureau P
Biologicals; 1990 Oct; 18(4):321-30. PubMed ID: 2285504
[TBL] [Abstract][Full Text] [Related]
4. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
[TBL] [Abstract][Full Text] [Related]
5. A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines.
Aavula SM; Abhinay G; Nimmagadda SV; Maithal K
J Immunoassay Immunochem; 2017; 38(4):400-410. PubMed ID: 28436708
[TBL] [Abstract][Full Text] [Related]
6. Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people.
Feyssaguet M; Dacheux L; Audry L; Compoint A; Morize JL; Blanchard I; Bourhy H
Vaccine; 2007 Mar; 25(12):2244-51. PubMed ID: 17224214
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans.
Muhamuda K; Madhusudana SN; Ravi V
Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182
[TBL] [Abstract][Full Text] [Related]
8. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
Jallet C; Tordo N
J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
[TBL] [Abstract][Full Text] [Related]
9. G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P
Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171
[TBL] [Abstract][Full Text] [Related]
10. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein.
Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM
J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752
[TBL] [Abstract][Full Text] [Related]
11. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
Turki I; Hammami A; Kharmachi H; Mousli M
Mol Immunol; 2014 Feb; 57(2):66-73. PubMed ID: 24091293
[TBL] [Abstract][Full Text] [Related]
12. Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein.
Nimmagadda SV; Aavula SM; Biradhar N; Rao VS; Shanmugham R; Chandran D; Thirumeni N; Singanallur NB; Villuppanoor SA
Clin Vaccine Immunol; 2010 Aug; 17(8):1261-8. PubMed ID: 20573881
[TBL] [Abstract][Full Text] [Related]
13. An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines.
Smith TG; Ellison JA; Ma X; Kuzmina N; Carson WC; Rupprecht CE
Vaccine; 2013 Jul; 31(33):3333-8. PubMed ID: 23742991
[TBL] [Abstract][Full Text] [Related]
14. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing.
Rooijakkers EJ; Uittenbogaard JP; Groen J; Osterhaus AD
J Virol Methods; 1996 Apr; 58(1-2):111-9. PubMed ID: 8783156
[TBL] [Abstract][Full Text] [Related]
15. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.
Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y
Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162
[TBL] [Abstract][Full Text] [Related]
16. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment.
Papaneri AB; Wirblich C; Marissen WE; Schnell MJ
Vaccine; 2013 Dec; 31(49):5897-902. PubMed ID: 24120673
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein.
Sun L; Chen Z; Yu L; Wei J; Li C; Jin J; Shen X; Lv X; Tang Q; Li D; Liang M
Appl Microbiol Biotechnol; 2012 Oct; 96(2):357-66. PubMed ID: 22678022
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus.
Matsumoto T; Yamada K; Noguchi K; Nakajima K; Takada K; Khawplod P; Nishizono A
Microbiol Immunol; 2010 Nov; 54(11):673-83. PubMed ID: 21044141
[TBL] [Abstract][Full Text] [Related]
19. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.
Morgeaux S; Poirier B; Ragan CI; Wilkinson D; Arabin U; Guinet-Morlot F; Levis R; Meyer H; Riou P; Shaid S; Volokhov D; Tordo N; Chapsal JM
Vaccine; 2017 Feb; 35(6):966-971. PubMed ID: 28081969
[TBL] [Abstract][Full Text] [Related]
20. A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.
Gairola S; Gautam M; Waghmare S
Hum Vaccin Immunother; 2020 Aug; 16(8):1857-1865. PubMed ID: 31971485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]